The clinical study of peripheral subcutaneous neuromodulation in postherpetic neuralgia treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58767633

Enrollment

120

Registered

2007-10-30

Start date

2007-09-01

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic Neuralgia (PHN) Nervous System Diseases Postherpetic Neuralgia (PHN)

Interventions

Arm 1: peripheral subcutaneous neuromodulation Arm 2: sham peripheral subcutaneous neuromodulation Arm 3: naive control group Treatment will continue f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients were between 60 and 90 years old 2. Patients must have pain present for more than 6 months after the healing of shingles skin rash 3. Patients at screening must have a score of greater than or equal to 40 mm on the pain visual analogue scale

Exclusion criteria

Exclusion criteria: 1. Patients withdrawn from the study 2. Patients can't take self-assessment of the pain due to PHN

Design outcomes

Primary

Measure	Time frame
Analgesic efficacy (Visual Analogue Scale [VAS]) and Quality Of Life (QOL) from 3 days to 1 month after neuromodulation.	—

Secondary

Measure	Time frame
1. QOL 2. 36-item Short Form health survey (SF-36) 3. Oral analgesic drugs dose 4. Three skin fiber (C-, Aâ and Aä) functional measurement All measured from 1 month to 6 months after neuromodulation.	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026